Last reviewed · How we verify
CD19CAR T-cells
At a glance
| Generic name | CD19CAR T-cells |
|---|---|
| Sponsor | University College, London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia (PHASE1)
- Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases (EARLY_PHASE1)
- T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (PHASE1)
- Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma (PHASE1)
- Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia (PHASE1)
- Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (PHASE1)
- Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (PHASE2)
- EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD19CAR T-cells CI brief — competitive landscape report
- CD19CAR T-cells updates RSS · CI watch RSS
- University College, London portfolio CI